nodes	percent_of_prediction	percent_of_DWPC	metapath
Maprotiline—CYP1A2—Carmustine—lymphatic system cancer	0.0759	0.536	CbGbCtD
Maprotiline—ABCB1—Mitoxantrone—lymphatic system cancer	0.0312	0.22	CbGbCtD
Maprotiline—ABCB1—Vincristine—lymphatic system cancer	0.0215	0.152	CbGbCtD
Maprotiline—ABCB1—Methotrexate—lymphatic system cancer	0.013	0.0918	CbGbCtD
Maprotiline—Convulsion—Fludarabine—lymphatic system cancer	0.00277	0.00323	CcSEcCtD
Maprotiline—Diarrhoea—Mechlorethamine—lymphatic system cancer	0.00276	0.00321	CcSEcCtD
Maprotiline—Hypoaesthesia—Bleomycin—lymphatic system cancer	0.00268	0.00312	CcSEcCtD
Maprotiline—Pancytopenia—Vincristine—lymphatic system cancer	0.00267	0.0031	CcSEcCtD
Maprotiline—Sweating increased—Mitoxantrone—lymphatic system cancer	0.00266	0.0031	CcSEcCtD
Maprotiline—Petechiae—Methotrexate—lymphatic system cancer	0.00264	0.00307	CcSEcCtD
Maprotiline—Confusional state—Fludarabine—lymphatic system cancer	0.00263	0.00307	CcSEcCtD
Maprotiline—Oedema—Fludarabine—lymphatic system cancer	0.00261	0.00304	CcSEcCtD
Maprotiline—Pancytopenia—Mitoxantrone—lymphatic system cancer	0.0026	0.00302	CcSEcCtD
Maprotiline—Infection—Fludarabine—lymphatic system cancer	0.0026	0.00302	CcSEcCtD
Maprotiline—Erectile dysfunction—Vincristine—lymphatic system cancer	0.00258	0.00301	CcSEcCtD
Maprotiline—Neuropathy peripheral—Carmustine—lymphatic system cancer	0.00257	0.00299	CcSEcCtD
Maprotiline—Vomiting—Mechlorethamine—lymphatic system cancer	0.00256	0.00299	CcSEcCtD
Maprotiline—Nervous system disorder—Fludarabine—lymphatic system cancer	0.00256	0.00298	CcSEcCtD
Maprotiline—Photosensitivity reaction—Vincristine—lymphatic system cancer	0.00256	0.00298	CcSEcCtD
Maprotiline—Thrombocytopenia—Fludarabine—lymphatic system cancer	0.00256	0.00298	CcSEcCtD
Maprotiline—Stomatitis—Carmustine—lymphatic system cancer	0.00256	0.00298	CcSEcCtD
Maprotiline—Rash—Mechlorethamine—lymphatic system cancer	0.00254	0.00296	CcSEcCtD
Maprotiline—Dermatitis—Mechlorethamine—lymphatic system cancer	0.00254	0.00296	CcSEcCtD
Maprotiline—Weight decreased—Vincristine—lymphatic system cancer	0.00254	0.00296	CcSEcCtD
Maprotiline—Hyperhidrosis—Fludarabine—lymphatic system cancer	0.00253	0.00294	CcSEcCtD
Maprotiline—Erectile dysfunction—Mitoxantrone—lymphatic system cancer	0.00252	0.00293	CcSEcCtD
Maprotiline—Flushing—Bleomycin—lymphatic system cancer	0.0025	0.00291	CcSEcCtD
Maprotiline—Weight increased—Mitoxantrone—lymphatic system cancer	0.00249	0.0029	CcSEcCtD
Maprotiline—Weight decreased—Mitoxantrone—lymphatic system cancer	0.00247	0.00288	CcSEcCtD
Maprotiline—Acute coronary syndrome—Vincristine—lymphatic system cancer	0.00247	0.00287	CcSEcCtD
Maprotiline—Myocardial infarction—Vincristine—lymphatic system cancer	0.00245	0.00286	CcSEcCtD
Maprotiline—Neuropathy peripheral—Vincristine—lymphatic system cancer	0.00245	0.00286	CcSEcCtD
Maprotiline—Feeling abnormal—Teniposide—lymphatic system cancer	0.00245	0.00285	CcSEcCtD
Maprotiline—Stomatitis—Vincristine—lymphatic system cancer	0.00244	0.00284	CcSEcCtD
Maprotiline—Drowsiness—Mitoxantrone—lymphatic system cancer	0.00244	0.00284	CcSEcCtD
Maprotiline—Gastrointestinal pain—Teniposide—lymphatic system cancer	0.00243	0.00283	CcSEcCtD
Maprotiline—Bone disorder—Methotrexate—lymphatic system cancer	0.0024	0.0028	CcSEcCtD
Maprotiline—Acute coronary syndrome—Mitoxantrone—lymphatic system cancer	0.0024	0.0028	CcSEcCtD
Maprotiline—Nausea—Mechlorethamine—lymphatic system cancer	0.00239	0.00279	CcSEcCtD
Maprotiline—Myocardial infarction—Mitoxantrone—lymphatic system cancer	0.00239	0.00278	CcSEcCtD
Maprotiline—Alopecia—Bleomycin—lymphatic system cancer	0.00238	0.00278	CcSEcCtD
Maprotiline—Stomatitis—Mitoxantrone—lymphatic system cancer	0.00238	0.00277	CcSEcCtD
Maprotiline—Jaundice—Mitoxantrone—lymphatic system cancer	0.00238	0.00277	CcSEcCtD
Maprotiline—Urticaria—Teniposide—lymphatic system cancer	0.00236	0.00275	CcSEcCtD
Maprotiline—Abdominal pain—Teniposide—lymphatic system cancer	0.00235	0.00274	CcSEcCtD
Maprotiline—Body temperature increased—Teniposide—lymphatic system cancer	0.00235	0.00274	CcSEcCtD
Maprotiline—Paraesthesia—Fludarabine—lymphatic system cancer	0.00235	0.00273	CcSEcCtD
Maprotiline—Hallucination—Carmustine—lymphatic system cancer	0.00234	0.00273	CcSEcCtD
Maprotiline—Hypoaesthesia—Carmustine—lymphatic system cancer	0.00234	0.00273	CcSEcCtD
Maprotiline—Dyspepsia—Fludarabine—lymphatic system cancer	0.0023	0.00268	CcSEcCtD
Maprotiline—Dysarthria—Methotrexate—lymphatic system cancer	0.00229	0.00267	CcSEcCtD
Maprotiline—Agranulocytosis—Mitoxantrone—lymphatic system cancer	0.00227	0.00265	CcSEcCtD
Maprotiline—Gastrointestinal disorder—Fludarabine—lymphatic system cancer	0.00226	0.00263	CcSEcCtD
Maprotiline—Fatigue—Fludarabine—lymphatic system cancer	0.00225	0.00262	CcSEcCtD
Maprotiline—Hypoaesthesia—Vincristine—lymphatic system cancer	0.00224	0.0026	CcSEcCtD
Maprotiline—Hallucination—Vincristine—lymphatic system cancer	0.00224	0.0026	CcSEcCtD
Maprotiline—Constipation—Fludarabine—lymphatic system cancer	0.00223	0.0026	CcSEcCtD
Maprotiline—Urinary tract disorder—Vincristine—lymphatic system cancer	0.00222	0.00258	CcSEcCtD
Maprotiline—Urethral disorder—Vincristine—lymphatic system cancer	0.0022	0.00257	CcSEcCtD
Maprotiline—Eye disorder—Carmustine—lymphatic system cancer	0.0022	0.00256	CcSEcCtD
Maprotiline—Hepatitis—Mitoxantrone—lymphatic system cancer	0.00219	0.00255	CcSEcCtD
Maprotiline—Flushing—Carmustine—lymphatic system cancer	0.00218	0.00254	CcSEcCtD
Maprotiline—Feeling abnormal—Fludarabine—lymphatic system cancer	0.00215	0.00251	CcSEcCtD
Maprotiline—Asthenia—Teniposide—lymphatic system cancer	0.00213	0.00248	CcSEcCtD
Maprotiline—Pruritus—Teniposide—lymphatic system cancer	0.0021	0.00245	CcSEcCtD
Maprotiline—Arrhythmia—Carmustine—lymphatic system cancer	0.0021	0.00245	CcSEcCtD
Maprotiline—Leukopenia—Bleomycin—lymphatic system cancer	0.0021	0.00245	CcSEcCtD
Maprotiline—Cardiac disorder—Vincristine—lymphatic system cancer	0.00208	0.00243	CcSEcCtD
Maprotiline—Alopecia—Carmustine—lymphatic system cancer	0.00208	0.00242	CcSEcCtD
Maprotiline—Body temperature increased—Fludarabine—lymphatic system cancer	0.00207	0.00241	CcSEcCtD
Maprotiline—Malnutrition—Carmustine—lymphatic system cancer	0.00205	0.00239	CcSEcCtD
Maprotiline—Angiopathy—Vincristine—lymphatic system cancer	0.00204	0.00237	CcSEcCtD
Maprotiline—Diarrhoea—Teniposide—lymphatic system cancer	0.00203	0.00237	CcSEcCtD
Maprotiline—Mediastinal disorder—Vincristine—lymphatic system cancer	0.00202	0.00236	CcSEcCtD
Maprotiline—Alopecia—Vincristine—lymphatic system cancer	0.00199	0.00231	CcSEcCtD
Maprotiline—Arrhythmia—Mitoxantrone—lymphatic system cancer	0.00195	0.00228	CcSEcCtD
Maprotiline—Gynaecomastia—Methotrexate—lymphatic system cancer	0.00194	0.00226	CcSEcCtD
Maprotiline—Alopecia—Mitoxantrone—lymphatic system cancer	0.00193	0.00225	CcSEcCtD
Maprotiline—Confusional state—Bleomycin—lymphatic system cancer	0.00193	0.00225	CcSEcCtD
Maprotiline—Vision blurred—Carmustine—lymphatic system cancer	0.00193	0.00225	CcSEcCtD
Maprotiline—Tremor—Carmustine—lymphatic system cancer	0.00192	0.00224	CcSEcCtD
Maprotiline—Oedema—Bleomycin—lymphatic system cancer	0.00192	0.00223	CcSEcCtD
Maprotiline—Infection—Bleomycin—lymphatic system cancer	0.0019	0.00222	CcSEcCtD
Maprotiline—Vomiting—Teniposide—lymphatic system cancer	0.00189	0.0022	CcSEcCtD
Maprotiline—Agitation—Carmustine—lymphatic system cancer	0.00188	0.00219	CcSEcCtD
Maprotiline—Thrombocytopenia—Bleomycin—lymphatic system cancer	0.00188	0.00218	CcSEcCtD
Maprotiline—Asthenia—Fludarabine—lymphatic system cancer	0.00187	0.00218	CcSEcCtD
Maprotiline—Rash—Teniposide—lymphatic system cancer	0.00187	0.00218	CcSEcCtD
Maprotiline—Dermatitis—Teniposide—lymphatic system cancer	0.00187	0.00218	CcSEcCtD
Maprotiline—Dysgeusia—Mitoxantrone—lymphatic system cancer	0.00186	0.00217	CcSEcCtD
Maprotiline—Headache—Teniposide—lymphatic system cancer	0.00186	0.00217	CcSEcCtD
Maprotiline—Pruritus—Fludarabine—lymphatic system cancer	0.00185	0.00215	CcSEcCtD
Maprotiline—Leukopenia—Carmustine—lymphatic system cancer	0.00183	0.00214	CcSEcCtD
Maprotiline—Agitation—Vincristine—lymphatic system cancer	0.0018	0.00209	CcSEcCtD
Maprotiline—Vision blurred—Mitoxantrone—lymphatic system cancer	0.00179	0.00209	CcSEcCtD
Maprotiline—Hypotension—Bleomycin—lymphatic system cancer	0.00179	0.00208	CcSEcCtD
Maprotiline—Diarrhoea—Fludarabine—lymphatic system cancer	0.00179	0.00208	CcSEcCtD
Maprotiline—Convulsion—Carmustine—lymphatic system cancer	0.00177	0.00207	CcSEcCtD
Maprotiline—Hypertension—Carmustine—lymphatic system cancer	0.00177	0.00206	CcSEcCtD
Maprotiline—Nausea—Teniposide—lymphatic system cancer	0.00177	0.00206	CcSEcCtD
Maprotiline—Leukopenia—Vincristine—lymphatic system cancer	0.00175	0.00204	CcSEcCtD
Maprotiline—Anxiety—Carmustine—lymphatic system cancer	0.00174	0.00202	CcSEcCtD
Maprotiline—Paraesthesia—Bleomycin—lymphatic system cancer	0.00172	0.002	CcSEcCtD
Maprotiline—Leukopenia—Mitoxantrone—lymphatic system cancer	0.0017	0.00199	CcSEcCtD
Maprotiline—Convulsion—Vincristine—lymphatic system cancer	0.00169	0.00197	CcSEcCtD
Maprotiline—Hypertension—Vincristine—lymphatic system cancer	0.00169	0.00197	CcSEcCtD
Maprotiline—Confusional state—Carmustine—lymphatic system cancer	0.00169	0.00196	CcSEcCtD
Maprotiline—Oedema—Carmustine—lymphatic system cancer	0.00167	0.00195	CcSEcCtD
Maprotiline—Infection—Carmustine—lymphatic system cancer	0.00166	0.00193	CcSEcCtD
Maprotiline—Vomiting—Fludarabine—lymphatic system cancer	0.00166	0.00193	CcSEcCtD
Maprotiline—Convulsion—Mitoxantrone—lymphatic system cancer	0.00165	0.00192	CcSEcCtD
Maprotiline—Rash—Fludarabine—lymphatic system cancer	0.00165	0.00192	CcSEcCtD
Maprotiline—Dermatitis—Fludarabine—lymphatic system cancer	0.00165	0.00192	CcSEcCtD
Maprotiline—Hypertension—Mitoxantrone—lymphatic system cancer	0.00164	0.00192	CcSEcCtD
Maprotiline—Thrombocytopenia—Carmustine—lymphatic system cancer	0.00164	0.00191	CcSEcCtD
Maprotiline—Headache—Fludarabine—lymphatic system cancer	0.00164	0.00191	CcSEcCtD
Maprotiline—Tachycardia—Carmustine—lymphatic system cancer	0.00163	0.0019	CcSEcCtD
Maprotiline—Anxiety—Mitoxantrone—lymphatic system cancer	0.00162	0.00188	CcSEcCtD
Maprotiline—Cerebrovascular accident—Methotrexate—lymphatic system cancer	0.00161	0.00187	CcSEcCtD
Maprotiline—Oedema—Vincristine—lymphatic system cancer	0.0016	0.00186	CcSEcCtD
Maprotiline—Infection—Vincristine—lymphatic system cancer	0.00159	0.00185	CcSEcCtD
Maprotiline—Feeling abnormal—Bleomycin—lymphatic system cancer	0.00158	0.00184	CcSEcCtD
Maprotiline—Osteoarthritis—Methotrexate—lymphatic system cancer	0.00158	0.00184	CcSEcCtD
Maprotiline—Confusional state—Mitoxantrone—lymphatic system cancer	0.00157	0.00183	CcSEcCtD
Maprotiline—Nervous system disorder—Vincristine—lymphatic system cancer	0.00157	0.00182	CcSEcCtD
Maprotiline—Thrombocytopenia—Vincristine—lymphatic system cancer	0.00156	0.00182	CcSEcCtD
Maprotiline—Hypotension—Carmustine—lymphatic system cancer	0.00156	0.00182	CcSEcCtD
Maprotiline—Oedema—Mitoxantrone—lymphatic system cancer	0.00155	0.00181	CcSEcCtD
Maprotiline—Nausea—Fludarabine—lymphatic system cancer	0.00155	0.00181	CcSEcCtD
Maprotiline—Infection—Mitoxantrone—lymphatic system cancer	0.00154	0.0018	CcSEcCtD
Maprotiline—Hyperhidrosis—Vincristine—lymphatic system cancer	0.00154	0.0018	CcSEcCtD
Maprotiline—Shock—Mitoxantrone—lymphatic system cancer	0.00153	0.00178	CcSEcCtD
Maprotiline—Thrombocytopenia—Mitoxantrone—lymphatic system cancer	0.00152	0.00177	CcSEcCtD
Maprotiline—Urticaria—Bleomycin—lymphatic system cancer	0.00152	0.00177	CcSEcCtD
Maprotiline—Tachycardia—Mitoxantrone—lymphatic system cancer	0.00152	0.00177	CcSEcCtD
Maprotiline—Body temperature increased—Bleomycin—lymphatic system cancer	0.00151	0.00176	CcSEcCtD
Maprotiline—Insomnia—Carmustine—lymphatic system cancer	0.00151	0.00176	CcSEcCtD
Maprotiline—Skin disorder—Mitoxantrone—lymphatic system cancer	0.00151	0.00176	CcSEcCtD
Maprotiline—Hyperhidrosis—Mitoxantrone—lymphatic system cancer	0.0015	0.00175	CcSEcCtD
Maprotiline—Paraesthesia—Carmustine—lymphatic system cancer	0.0015	0.00175	CcSEcCtD
Maprotiline—Hypotension—Vincristine—lymphatic system cancer	0.00149	0.00174	CcSEcCtD
Maprotiline—Somnolence—Carmustine—lymphatic system cancer	0.00149	0.00173	CcSEcCtD
Maprotiline—Ataxia—Methotrexate—lymphatic system cancer	0.00148	0.00173	CcSEcCtD
Maprotiline—Liver function test abnormal—Methotrexate—lymphatic system cancer	0.00145	0.00169	CcSEcCtD
Maprotiline—Hypotension—Mitoxantrone—lymphatic system cancer	0.00145	0.00169	CcSEcCtD
Maprotiline—Insomnia—Vincristine—lymphatic system cancer	0.00144	0.00168	CcSEcCtD
Maprotiline—Gastrointestinal disorder—Carmustine—lymphatic system cancer	0.00144	0.00168	CcSEcCtD
Maprotiline—Paraesthesia—Vincristine—lymphatic system cancer	0.00143	0.00167	CcSEcCtD
Maprotiline—Constipation—Carmustine—lymphatic system cancer	0.00143	0.00167	CcSEcCtD
Maprotiline—Breast disorder—Methotrexate—lymphatic system cancer	0.00142	0.00166	CcSEcCtD
Maprotiline—Toxic epidermal necrolysis—Methotrexate—lymphatic system cancer	0.00142	0.00165	CcSEcCtD
Maprotiline—Paraesthesia—Mitoxantrone—lymphatic system cancer	0.0014	0.00163	CcSEcCtD
Maprotiline—Somnolence—Mitoxantrone—lymphatic system cancer	0.00138	0.00161	CcSEcCtD
Maprotiline—Gastrointestinal disorder—Vincristine—lymphatic system cancer	0.00138	0.00161	CcSEcCtD
Maprotiline—Feeling abnormal—Carmustine—lymphatic system cancer	0.00138	0.0016	CcSEcCtD
Maprotiline—Fatigue—Vincristine—lymphatic system cancer	0.00138	0.0016	CcSEcCtD
Maprotiline—Asthenia—Bleomycin—lymphatic system cancer	0.00137	0.0016	CcSEcCtD
Maprotiline—Dyspepsia—Mitoxantrone—lymphatic system cancer	0.00137	0.00159	CcSEcCtD
Maprotiline—Gastrointestinal pain—Carmustine—lymphatic system cancer	0.00137	0.00159	CcSEcCtD
Maprotiline—Constipation—Vincristine—lymphatic system cancer	0.00136	0.00159	CcSEcCtD
Maprotiline—Pruritus—Bleomycin—lymphatic system cancer	0.00136	0.00158	CcSEcCtD
Maprotiline—Eosinophilia—Methotrexate—lymphatic system cancer	0.00135	0.00157	CcSEcCtD
Maprotiline—Fatigue—Mitoxantrone—lymphatic system cancer	0.00134	0.00156	CcSEcCtD
Maprotiline—Constipation—Mitoxantrone—lymphatic system cancer	0.00133	0.00155	CcSEcCtD
Maprotiline—Abdominal pain—Carmustine—lymphatic system cancer	0.00132	0.00154	CcSEcCtD
Maprotiline—Body temperature increased—Carmustine—lymphatic system cancer	0.00132	0.00154	CcSEcCtD
Maprotiline—Gastrointestinal pain—Vincristine—lymphatic system cancer	0.00131	0.00152	CcSEcCtD
Maprotiline—Pancytopenia—Methotrexate—lymphatic system cancer	0.00129	0.00151	CcSEcCtD
Maprotiline—Feeling abnormal—Mitoxantrone—lymphatic system cancer	0.00128	0.00149	CcSEcCtD
Maprotiline—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	0.00127	0.00148	CcSEcCtD
Maprotiline—Body temperature increased—Vincristine—lymphatic system cancer	0.00126	0.00147	CcSEcCtD
Maprotiline—Abdominal pain—Vincristine—lymphatic system cancer	0.00126	0.00147	CcSEcCtD
Maprotiline—Erectile dysfunction—Methotrexate—lymphatic system cancer	0.00125	0.00146	CcSEcCtD
Maprotiline—Photosensitivity reaction—Methotrexate—lymphatic system cancer	0.00124	0.00145	CcSEcCtD
Maprotiline—Urticaria—Mitoxantrone—lymphatic system cancer	0.00123	0.00144	CcSEcCtD
Maprotiline—Abdominal pain—Mitoxantrone—lymphatic system cancer	0.00123	0.00143	CcSEcCtD
Maprotiline—Body temperature increased—Mitoxantrone—lymphatic system cancer	0.00123	0.00143	CcSEcCtD
Maprotiline—Vomiting—Bleomycin—lymphatic system cancer	0.00122	0.00142	CcSEcCtD
Maprotiline—Infestation NOS—Methotrexate—lymphatic system cancer	0.00121	0.00141	CcSEcCtD
Maprotiline—Infestation—Methotrexate—lymphatic system cancer	0.00121	0.00141	CcSEcCtD
Maprotiline—Drowsiness—Methotrexate—lymphatic system cancer	0.00121	0.00141	CcSEcCtD
Maprotiline—Rash—Bleomycin—lymphatic system cancer	0.00121	0.00141	CcSEcCtD
Maprotiline—Dermatitis—Bleomycin—lymphatic system cancer	0.00121	0.00141	CcSEcCtD
Maprotiline—Stevens-Johnson syndrome—Methotrexate—lymphatic system cancer	0.0012	0.0014	CcSEcCtD
Maprotiline—Asthenia—Carmustine—lymphatic system cancer	0.0012	0.0014	CcSEcCtD
Maprotiline—Stomatitis—Methotrexate—lymphatic system cancer	0.00118	0.00138	CcSEcCtD
Maprotiline—Hepatobiliary disease—Methotrexate—lymphatic system cancer	0.00115	0.00134	CcSEcCtD
Maprotiline—Asthenia—Vincristine—lymphatic system cancer	0.00115	0.00133	CcSEcCtD
Maprotiline—Diarrhoea—Carmustine—lymphatic system cancer	0.00114	0.00133	CcSEcCtD
Maprotiline—Nausea—Bleomycin—lymphatic system cancer	0.00114	0.00133	CcSEcCtD
Maprotiline—Agranulocytosis—Methotrexate—lymphatic system cancer	0.00113	0.00132	CcSEcCtD
Maprotiline—Asthenia—Mitoxantrone—lymphatic system cancer	0.00112	0.0013	CcSEcCtD
Maprotiline—Dizziness—Carmustine—lymphatic system cancer	0.00111	0.00129	CcSEcCtD
Maprotiline—Diarrhoea—Vincristine—lymphatic system cancer	0.00109	0.00127	CcSEcCtD
Maprotiline—Hepatitis—Methotrexate—lymphatic system cancer	0.00109	0.00127	CcSEcCtD
Maprotiline—Urinary tract disorder—Methotrexate—lymphatic system cancer	0.00108	0.00125	CcSEcCtD
Maprotiline—Urethral disorder—Methotrexate—lymphatic system cancer	0.00107	0.00124	CcSEcCtD
Maprotiline—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.00106	0.00124	CcSEcCtD
Maprotiline—Vomiting—Carmustine—lymphatic system cancer	0.00106	0.00124	CcSEcCtD
Maprotiline—Dizziness—Vincristine—lymphatic system cancer	0.00106	0.00123	CcSEcCtD
Maprotiline—Rash—Carmustine—lymphatic system cancer	0.00105	0.00123	CcSEcCtD
Maprotiline—Dermatitis—Carmustine—lymphatic system cancer	0.00105	0.00123	CcSEcCtD
Maprotiline—Headache—Carmustine—lymphatic system cancer	0.00105	0.00122	CcSEcCtD
Maprotiline—Erythema multiforme—Methotrexate—lymphatic system cancer	0.00103	0.0012	CcSEcCtD
Maprotiline—Eye disorder—Methotrexate—lymphatic system cancer	0.00102	0.00119	CcSEcCtD
Maprotiline—Tinnitus—Methotrexate—lymphatic system cancer	0.00102	0.00118	CcSEcCtD
Maprotiline—Vomiting—Vincristine—lymphatic system cancer	0.00101	0.00118	CcSEcCtD
Maprotiline—Cardiac disorder—Methotrexate—lymphatic system cancer	0.00101	0.00118	CcSEcCtD
Maprotiline—Rash—Vincristine—lymphatic system cancer	0.00101	0.00117	CcSEcCtD
Maprotiline—Dermatitis—Vincristine—lymphatic system cancer	0.00101	0.00117	CcSEcCtD
Maprotiline—Headache—Vincristine—lymphatic system cancer	0.001	0.00116	CcSEcCtD
Maprotiline—Nausea—Carmustine—lymphatic system cancer	0.000993	0.00116	CcSEcCtD
Maprotiline—Angiopathy—Methotrexate—lymphatic system cancer	0.000989	0.00115	CcSEcCtD
Maprotiline—Vomiting—Mitoxantrone—lymphatic system cancer	0.000988	0.00115	CcSEcCtD
Maprotiline—Mediastinal disorder—Methotrexate—lymphatic system cancer	0.000982	0.00114	CcSEcCtD
Maprotiline—Rash—Mitoxantrone—lymphatic system cancer	0.00098	0.00114	CcSEcCtD
Maprotiline—Dermatitis—Mitoxantrone—lymphatic system cancer	0.000979	0.00114	CcSEcCtD
Maprotiline—Headache—Mitoxantrone—lymphatic system cancer	0.000974	0.00113	CcSEcCtD
Maprotiline—Alopecia—Methotrexate—lymphatic system cancer	0.000963	0.00112	CcSEcCtD
Maprotiline—Malnutrition—Methotrexate—lymphatic system cancer	0.000949	0.00111	CcSEcCtD
Maprotiline—Nausea—Vincristine—lymphatic system cancer	0.000948	0.0011	CcSEcCtD
Maprotiline—Dysgeusia—Methotrexate—lymphatic system cancer	0.000929	0.00108	CcSEcCtD
Maprotiline—Nausea—Mitoxantrone—lymphatic system cancer	0.000923	0.00108	CcSEcCtD
Maprotiline—Vision blurred—Methotrexate—lymphatic system cancer	0.000894	0.00104	CcSEcCtD
Maprotiline—Leukopenia—Methotrexate—lymphatic system cancer	0.000849	0.000989	CcSEcCtD
Maprotiline—Convulsion—Methotrexate—lymphatic system cancer	0.000822	0.000958	CcSEcCtD
Maprotiline—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lymphatic system cancer	0.000802	0.000935	CcSEcCtD
Maprotiline—Confusional state—Methotrexate—lymphatic system cancer	0.000781	0.00091	CcSEcCtD
Maprotiline—Infection—Methotrexate—lymphatic system cancer	0.000769	0.000896	CcSEcCtD
Maprotiline—Nervous system disorder—Methotrexate—lymphatic system cancer	0.000759	0.000885	CcSEcCtD
Maprotiline—Thrombocytopenia—Methotrexate—lymphatic system cancer	0.000758	0.000883	CcSEcCtD
Maprotiline—Skin disorder—Methotrexate—lymphatic system cancer	0.000752	0.000876	CcSEcCtD
Maprotiline—Hyperhidrosis—Methotrexate—lymphatic system cancer	0.000749	0.000872	CcSEcCtD
Maprotiline—Hypotension—Methotrexate—lymphatic system cancer	0.000724	0.000843	CcSEcCtD
Maprotiline—Insomnia—Methotrexate—lymphatic system cancer	0.0007	0.000816	CcSEcCtD
Maprotiline—Paraesthesia—Methotrexate—lymphatic system cancer	0.000695	0.00081	CcSEcCtD
Maprotiline—Somnolence—Methotrexate—lymphatic system cancer	0.000688	0.000802	CcSEcCtD
Maprotiline—Dyspepsia—Methotrexate—lymphatic system cancer	0.000682	0.000794	CcSEcCtD
Maprotiline—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	0.000669	0.000779	CcSEcCtD
Maprotiline—Fatigue—Methotrexate—lymphatic system cancer	0.000668	0.000778	CcSEcCtD
Maprotiline—Feeling abnormal—Methotrexate—lymphatic system cancer	0.000638	0.000743	CcSEcCtD
Maprotiline—Gastrointestinal pain—Methotrexate—lymphatic system cancer	0.000633	0.000738	CcSEcCtD
Maprotiline—Urticaria—Methotrexate—lymphatic system cancer	0.000615	0.000717	CcSEcCtD
Maprotiline—Abdominal pain—Methotrexate—lymphatic system cancer	0.000612	0.000713	CcSEcCtD
Maprotiline—Body temperature increased—Methotrexate—lymphatic system cancer	0.000612	0.000713	CcSEcCtD
Maprotiline—Asthenia—Methotrexate—lymphatic system cancer	0.000556	0.000647	CcSEcCtD
Maprotiline—Pruritus—Methotrexate—lymphatic system cancer	0.000548	0.000638	CcSEcCtD
Maprotiline—Diarrhoea—Methotrexate—lymphatic system cancer	0.00053	0.000617	CcSEcCtD
Maprotiline—Dizziness—Methotrexate—lymphatic system cancer	0.000512	0.000597	CcSEcCtD
Maprotiline—Vomiting—Methotrexate—lymphatic system cancer	0.000492	0.000574	CcSEcCtD
Maprotiline—Rash—Methotrexate—lymphatic system cancer	0.000488	0.000569	CcSEcCtD
Maprotiline—Dermatitis—Methotrexate—lymphatic system cancer	0.000488	0.000568	CcSEcCtD
Maprotiline—Headache—Methotrexate—lymphatic system cancer	0.000485	0.000565	CcSEcCtD
Maprotiline—Nausea—Methotrexate—lymphatic system cancer	0.00046	0.000536	CcSEcCtD
